Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8+ T cell control of tumor challenge in mice
Gabriel Dagotto, Alessandro Colarusso, Robert C Patio, David Li, Tochi Anioke, Victoria Giffin, Ruoran Guan, Trisha Anand, Esther Mbiwan, Malika Aid, Dan Barouch · 2024
Read Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8+ T cell control of tumor challenge in mice by Gabriel Dagotto, Alessandro Colarusso, Robert C Patio, David Li, Tochi Anioke, Victoria Giffin, Ruoran Guan, Trisha Anand, Esther Mbiwan, Malika Aid, Dan Barouch (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11660326.txt.
Description
Gabriel Dagotto and co-authors tested a viral cancer vaccine in mice in two thousand twenty-four. Cancer vaccines can target tumor-specific neoantigens. Peptide delivery is the common current route. Adenovirus vectors spark strong killer T cell responses. Their use for neoantigens was largely unexplored. The team built vaccines in a proven adenovirus strain.
Two mouse tumor models tested the vaccines. One was melanoma, the other colon cancer. Vector vaccines were compared with peptide ones. Protection was preventive: vaccine first, tumor challenge after. The best vector design expanded huge T cell pools. Those pools controlled tumor challenge better. Viral delivery may beat peptides for cancer vaccines. Human translation needs safety work first.
Catalog record
| CREATOR | Gabriel Dagotto, Alessandro Colarusso, Robert C Patio, David Li, Tochi Anioke, Victoria Giffin, Ruoran Guan, Trisha Anand, Esther Mbiwan, Malika Aid, Dan Barouch |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |